Annexon Business Summary

Annexon, Inc. (ANNX) is a clinical-stage biopharmaceutical company utilizing a capital-intensive R&D business model that focuses on the discovery and development of first-in-class therapies for classical complement-mediated disorders. The company generates revenue primarily through equity financing and public offerings—most recently securing approximately $86 million in late 2025—to fund its three core business segments: autoimmunity, neurodegeneration, and ophthalmology. Its value proposition is anchored in a proprietary platform targeting C1q to prevent synapse loss and tissue damage, with lead candidates tanruprubart (ANX005) for Guillain-Barré syndrome and vonaprument (ANX007) for geographic atrophy currently in registrational phases. Annexon competes with industry players like Apellis Pharmaceuticals, Hansa Biopharma, and Dyne Therapeutics, distinguishing itself through its unique upstream inhibition strategy that targets the very start of the complement cascade. Annexon was co-founded by Arnon Rosenthal, a serial entrepreneur who also founded Alector and Rinat Neurosciences, and the late Ben Barres, a pioneer in neurobiology from Stanford University. The executive team is headed by President and CEO Douglas Love, Esq., a former Elan Pharmaceuticals executive with a deep background in biotechnology law and operations. Supporting leadership includes Jennifer Lew as CFO, Dr. Ted Yednock as Chief Innovation Officer, Dr. Jamie Dananberg as Chief Medical Officer, and Dr. Rick Artis as Chief Scientific Officer. The company maintains a high-pedigree investor base including Bain Capital Life Sciences, New Enterprise Associates, and Blackstone, while its board is chaired by Thomas G. Wiggans and includes influential figures like Muneer Satter and Dr. William H. Carson.